



Botulinum Toxin Treatment for Spasticity and Pain

Guest Editor:

Dr. Domenico Intiso

Unit of Neuro-Rehabilitation and Rehabilitation Medicine, IRCCS 'Casa Sollievo della Sofferenza', Viale dei Cappuccini, San Giovanni Rotondo, 71013 Foggia, Italy

Deadline for manuscript submissions:

closed (30 November 2021)

Message from the Guest Editor

Although several pharmacological and not pharmacological treatments have been used in managing spasticity, botulinum toxin (BoNT) is the first line of therapy in focal spasticity. However, several questions remain unclear that encompass pathophysiological mechanisms (peripheral and central), modality of administration, site (single or multiple levels), dilution, severity of spasticity and dosage (high dosage), adjunct tools (cast, exercises, electrical stimulation), and the effect on functional recovery.

Therapies in treating pain and neuropathic pain may be poorly effective. BoNT has been proposed as a promising and efficacious therapeutic strategy, but likewise and even more so than spasticity treatment, many questions and issues remain unsolved.

This Special Issue will focus the role of BoNT in the management of spasticity and pain, addressing unclear questions and new approaches.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Jay Fox

Department of Microbiology,
University of Virginia,
Charlottesville, VA, USA

Message from the Editor-in-Chief

Toxinology is an incredibly diverse area of study, ranging from field surveys of environmental toxins to the study of toxin action at the molecular level. The editorial board and staff of *Toxins* are dedicated to providing a timely, peer-reviewed outlet for exciting, innovative primary research articles and concise, informative reviews from investigators in the myriad of disciplines contributing to our knowledge on toxins. We are committed to meeting the needs of the toxin research community by offering useful and timely reviews of all manuscripts submitted. Please consider *Toxins* when submitting your work for publication.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, AGRIS, and other databases.**

Journal Rank: JCR - Q1 (Toxicology) / CiteScore - Q1 (Toxicology)

Contact Us

Toxins Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/toxins
toxins@mdpi.com
[X@Toxins_Mdpi](#)